Key Takeaway
Retatrutide vs Every Other Weight Loss Drug Ranked. Research-backed information on retatrutide from FormBlends, your trusted telehealth weight loss provider.
Retatrutide is a next-generation triple-action weight loss medication currently in Phase 3 clinical trials. It targets GIP, GLP-1, and glucagon receptors simultaneously, producing the largest average weight loss of any obesity medication studied to date . Here is what we know so far about retatrutide vs every other weight loss drug ranked.
FormBlends
FormBlends is a U.S. telehealth platform that prescribes compounded semaglutide and tirzepatide. Patients complete an online intake, a licensed provider reviews eligibility, and medication ships from a 503A compounding pharmacy. Monthly pricing starts at $199. Start your intake.
What Makes Retatrutide Different from Other Weight Loss Medications?
Retatrutide stands apart because it's the first obesity medication to activate three hormone receptors:
- GLP-1 receptor: Reduces appetite and slows gastric emptying (same target as semaglutide)
- GIP receptor: Enhances insulin sensitivity and fat metabolism (same additional target as tirzepatide)
- Glucagon receptor: Increases energy expenditure and promotes fat oxidation, a mechanism unique to retatrutide among weight loss drugs
This triple action produced average weight loss of 24.2% in Phase 2 trials at the highest dose over 48 weeks[1]. Some participants lost more than 30% of their starting weight.
What Do We Know About Retatrutide vs Every Other Weight Loss Drug Ranked?
Based on the available clinical trial data, here is what the research tells us about retatrutide vs every other weight loss drug ranked:
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →View data table
| Category | Mean Body Weight Loss (%) | Detail |
|---|---|---|
| Placebo | 2 | ~2% weight loss |
| 4 mg | 17 | ~17% at 48 weeks |
| 8 mg | 22 | ~22% at 48 weeks |
| 12 mg | 24 | ~24% at 48 weeks |
- Phase 2 trials involved 338 adults with obesity over 48 weeks
- The medication was administered as a weekly subcutaneous injection
- Dose-dependent weight loss was observed, with higher doses producing greater results
- Side effects were primarily gastrointestinal (nausea, diarrhea, vomiting) and generally decreased over time
Phase 3 trials are currently underway and will provide more thorough data on long-term safety and efficacy.
When Will Retatrutide Be Available?
Retatrutide is currently in Phase 3 clinical trials. If these trials confirm the Phase 2 results, FDA approval could come as early as late 2025 or 2026 . But regulatory timelines can shift based on trial outcomes and FDA review processes.
FormBlends is preparing to offer retatrutide through our telehealth platform as soon as it receives FDA approval. In the meantime, we offer effective alternatives including compounded semaglutide and compounded tirzepatide.
What Can I Do Right Now?
You don't need to wait for retatrutide to start losing weight. Current GLP-1 medications available through FormBlends have helped thousands of patients achieve significant results:
- Semaglutide: average weight loss of 15-17%
- Tirzepatide: average weight loss of 20-22%
Starting treatment now also positions you well for a potential transition to retatrutide in the future, if your physician recommends it.
Medical References
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. [PubMed | ClinicalTrials.gov | DOI]
Stay Informed About Retatrutide
FormBlends will keep our patients updated on retatrutide developments as they happen. Complete your free online evaluation today to connect with a licensed physician and explore your weight loss options right now.